Pioneering Consumer Healthcare with Innovative Brands and Strategic Partnerships

Wellnex Life Ltd, an Australian company, develops, licenses, and markets healthcare products such as Wakey Wakey, Nighty Night, Pharmacy Own, The Iron Company, Mr Bright, and Pain Away. It has licensing agreements with Haleon and Arrotex. Through a joint venture with OneLife Botanical and Chemist Warehouse, it offers SAS-B medicinal cannabis under the Wellness Life brand. Wellnex Life also owns TGA registration for liquid soft gel analgesics, supplying them to pharmaceutical brands in Australia and internationally. Its products are distributed through pharmacy wholesale, grocery retailers, and supermarkets in Australia.

Our most frequently asked question... Our service is free for investors, and we do not sell subscriptions. We search for small ASX-listed companies and profile the ones we think may have investment potential. Fortunately, some companies we profile see the value in attracting new investors and engage us to boost the visibility of their profiles - these are marked "promoted" for transparency. This allows us to maintain this website and continue doing what we love without asking you to foot the bill. Thank you for visiting and if you have any questions please do not hesitate to ask.

Company

Wellnex Life Limited
Website

wellnexlife.com.au
Sector

Pharmaceuticals
Industry

Pharmaceuticals

Code

ASX:WNX
Socials

Company Overview

Wellnex Life Ltd, an Australian company, focuses on the consumer healthcare business. It develops, licenses, and markets various healthcare products and brands, including Wakey Wakey, Nighty Night, Pharmacy Own, The Iron Company, Mr Bright, and Pain Away. The company holds intellectual property licensing agreements with Haleon and Arrotex. Through a joint venture with OneLife Botanical and Chemist Warehouse, Wellnex Life offers SAS-B medicinal cannabis under the Wellness Life brand and Wagner Health Liquigesic. It also owns the Therapeutic Goods Administration (TGA) registration for various liquid soft gel analgesics, supplying them to pharmaceutical brands in Australia and internationally. Wellnex Life's products are distributed through Australia's pharmacy wholesale retail, grocery retailers, and supermarkets.

Share this profile:

Pioneering Consumer Healthcare with Innovative Brands and Strategic Partnerships.

Wellnex Life have aquired a portfolio of market leading brands, and are now rolling out a distribution strategy across multiple partnerships including the Chemist Warehouse group of pharmacies.

May 2024 Desk Note

Click here to read our latest update and revised outlook

View Here

Wellnex Life Adjusts FY24 Forecasts Amid Regulatory Delays, Anticipates Strong Growth in FY25

Wellnex Life Ltd has updated its FY24 financial projections due to operational headwinds, leading to significant revisions in its initial analysis. The company's expansion with Haleon has been delayed to the first half of FY25 because of regulatory bottlenecks in processing over-the-counter applications and manufacturing clearance. This delay has also affected orders from Arrotex and the joint venture with Chemist Warehouse, Wagner Health Liquigesics. Despite these challenges, Wellnex Life expects significant revenue growth in FY25. The settlement of Pain Away in late December and its subsequent strong performance have led to operational profitability in February 2024. This demonstrates the company's resilience and effective strategy of diversifying revenue streams. Although the regulatory delays have impacted the FY24 financial outlook, the recent operational profitability and supply-side developments are positive indicators. With a strengthened board and expanded Haleon partnership, Wellnex Life is well-positioned for growth in the coming periods.

Initiation of Coverage Report

Click here to read our November 2023 research Report.

View Here

Directors & Management

The Wellnex Life senior management team have a highly complimentary skill set and a track record of success to drive future growth

Zack Bozinovski

Managing Director

Mario Tascone

Non-Executive Chairman

Andrew Vidler

Independent Non-Executive Director

Jeffrey Yeh

Non-Executive Director

George Karafotias

Cheif Executive Officer

Eric Jiang

Independent Non-Executive Director

Information current at 17 May 2024

This section contains information provided by Wellnex Life Limited, with the exception of any sections labeled as "risks". Although all due care has been taken, Mawson Graham ("SmallCapInsider") does not warrant the accuracy of the information provided in this section. It is not intended as an offer, invitation solicitation or recommendation with respect to the purchase or sale of any securities. The above information should not be relied upon as the sole representation of any matter that a potential investor should consider in evaluating Wellnex Life Limited. Its affiliates or any of its directors, agents, officers or employees do not make any representation or warranty, express or implied, as to or endorsement of, the accuracy or completeness of any information, statements, representations or forecasts contained above, and they do not accept any liability for any statement made in, or omitted from, the above. Prospective investors should make their own independent evaluation of an investment in Wellnex Life Limited. This information may contain forward looking statements concerning Wellnex Life Limited. Forward-looking statements are not statements of historical fact and actual events and results may differ materially from those described in the forward looking statements as a result of a variety of risks, uncertainties and other factors. Forward-looking statements are inherently subject to business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause the Company’s actual results to differ materially from those expressed or implied in any forward-looking information provided by Wellnex Life Limited, or on behalf of Wellnex Life Limited. Forward looking statements are based on Wellnex Life Limited's beliefs, opinions and estimates. No obligation is assumed to update forward looking statements if these beliefs, opinions and estimates should change or to reflect other future developments.

Company Videos

4 Videos

Wellnex Life (ASX:WNX) New Chair, PainAway Acquisition & Dual Listing on the LSE E23

BPC is excited to present an exclusive conversation with George Karafotias, CEO of Wellnex Life and the new Non-Executive Chair, Mario Tascone as they discuss the game-changing acquisition of PainAway and the exciting decision to dual list on the London Stock Exchange. Join host Jack Colreavy, CFA, as he explores the unique hurdles they faced and the strategy behind the Company’s step towards the LSE. For further information on this #InvestmentOpportunity, please contact James Whelan.

Wellnex Life - Corporate Showcase Episode 20

Exclusive Investor Insights: Listen to Zack Bozinovski from Wellnex Life (ASX:WNX) as he discusses key investor highlights, covering the acquisition of #painAway, JV with Chemist Warehouse, global partnership with Haleon and the company strategy over the next 6 to 12 months as they are currently raising capital. For more information on the #investmentopportunity, please contact Michael Jeffery or James Whelan.

Interview with George Karafotias of Wellenx Life (ASX:WNX)

BPC is excited to share an exclusive interview with George Karafotias, CEO of Wellnex Life(ASX: WNX). Key Highlights: 1. Wellnex Life achieved record profitability, with over $2 million in branded sales for April. Margins increased from 11% to close to 40%. 2. The acquisition of #PainAway contributed to this profitability, along with the organic growth of other brands within the company, which are experiencing consistent month-on-month growth. A huge congratulations to George Karafotias, Zack Bozinovski, the board and the team at WNX for reaching this exciting milestone! #WellnexLife #ASX #ASXnews #Stocktowatch #InvestmentOpportunity

Wellnex Life sees innovation as organic growth drivers in health and wellness

Wellnex Life Ltd (ASX:WNX) CEO George Karafotias speaks to Proactive about Wellnex's strategy for growth in the Australian health and wellness market. Wellnex recently signed a supply agreement with industry giant GSK for "Australia's first liquid paracetamol product in a soft gel" and Karafotias believes a strategy of creating innovative consumer healthcare products is now drawing the attention of retailers and consumers. Karafotias adds that Wellnex Life will continue to focus on creating innovative new products, including medicinal products, as these are more attractive to retailers.

News Coverage

Current news mentioning Wellnex Life Limited from top publishers around the web.

No news coverage found...

Key Announcements

Management comments and explanations on key company announcements.

Title

Date

Desk Note - Revised Financial Projections and Valuation Outlook

Thursday 16/05/2024

Record Wellnex Own Brand Sales in April

Thursday 09/05/2024

ASX Announcement - Wellnex capitalises on Wakey Wakey brand success with an additional two new products launched

Wednesday 08/05/2024

Wellnex to dual list on the London Stock Exchange

Tuesday 23/04/2024

23/05/2024

Need a full list of every announcement? Visit ASX

How do I invest?

Considering investing in Wellnex Life Limited?
Here's how to get started.

1

Create account

Open an account with an online broker of your choice. If you do not have an existing broker, consider Vested Equities' A$9.50 flat fee platform.
Sign up now »
2

Search for ASX:WNX

On your online investment platform search for the stock ticker code ASX:WNX to bring up the company's shares.
3

Buy shares

Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.

Trade for $9.50